Maximizing Glycemic Benefits of Using Faster Insulin Formulations in Type 1 Diabetes: In Silico Analysis Under Open- and Closed-Loop Conditions

• Published in: Diabetes technology & therapeutics Vol. 25; no. 4; p. 219
• Main Authors: Diaz C, Jenny L, Colmegna, Patricio, Breton, Marc D
• Format: Journal Article
• Language: English
• Published: United States 01-04-2023
• Subjects: Adult; Blood Glucose; Computer Simulation; Diabetes Mellitus, Type 1 - drug therapy; Humans; Hypoglycemic Agents - therapeutic use; Insulin - therapeutic use; Insulin Aspart - therapeutic use; Insulin Infusion Systems; Insulin, Regular, Human - therapeutic use; Automated insulin delivery; Therapy optimization; Ultrarapid insulin; Type 1 diabetes; Pharmacokinetic/pharmacodynamic profile
• ISSN: 1557-8593
• DOI: 10.1089/dia.2022.0468

Ultrarapid-acting insulin analogs that could improve or even prevent postprandial hyperglycemia are now available for both research and clinical care. However, clear glycemic benefits remain elusive, especially when combined with automated insulin delivery (AID) systems. In this work, we study two insulin formulations in silico and highlight adjustments of both open-loop and closed-loop insulin delivery therapies as a critical step to achieve clinically meaningful improvements.
Subcutaneous insulin transport models for two faster analogs, Fiasp (Novo Nordisk, Bagsværd, Denmark) and AT247 (Arecor, Saffron Walden, United Kingdom), were identified using data collected from prior clamp experiments, and integrated into the UVA/Padova type 1 diabetes simulator (adult cohort,
 = 100). Pump therapy parameters and the aggressiveness of our full closed-loop algorithm were adapted to the new insulin pharmacokinetic and pharmacodynamic profiles through a sequence of in silico studies. Finally, we assessed these analogs' glycemic impact with and without modified therapy parameters in simulated conditions designed to match clinical trial data.
Simply switching to faster insulin analogs shows limited improvements in glycemic outcomes. However, when insulin acceleration is accompanied by therapy adaptation, clinical significance is found comparing time-in-range (70-180 mg/dL) with Aspart versus AT247 in open-loop (+5.1%); and Aspart versus Fiasp (+5.4%) or AT247 (+10.6%) in full closed-loop with no clinically significant differences in the exposure to hypoglycemia.
In silico results suggest that properly adjusting intensive insulin therapy profiles, or AID tuning, to faster insulin analogs is necessary to obtain clinically significant improvements in glucose control.